论文部分内容阅读
目的:分析用药方案为糖皮质激素吸入配合茶碱与联合长效β_2受体激动剂治疗哮喘的效果比较。方法:研究对象纳入2014年4月至2015年8月98例哮喘病人,将其随机分组。两组均施行对症支持和处理,Ⅰ组用药方案为糖皮质激素吸入配合茶碱,Ⅱ组用药方案为糖皮质激素吸入配合长效β_2受体激动剂。对比分析两组病人疗效、第一秒用力呼气量(FEV_1)、呼气峰流速(PEF)、症状评分和不良反应。结果:Ⅱ组病人治疗效果、FEV_1、PEF、症状评分均跟I组接近,组间进行统计学检验无显著差异(P>0.05)。从安全性看,Ⅱ组不良反应发生率低于对照组(P<0.05)。结论:糖皮质激素吸入配合茶碱与长效β_2受体激动剂治疗哮喘均有一定作用,但长效β_2受体激动剂安全性更高,可结合病人情况选择。
OBJECTIVE: To analyze the effect of glucocorticoid inhalation combined with theophylline and long-acting β_2 receptor agonist in the treatment of asthma. METHODS: The subjects included 98 asthmatic patients from April 2014 to August 2015 and were randomized into groups. Symptomatic support and treatment were administered in both groups. Group I was inhaled with glucocorticoid and theophylline. Group II was inhaled with glucocorticoid and long-acting beta-2 receptor agonist. The curative effect, FEV 1, PEF, symptom scores and adverse reactions of two groups were compared and analyzed. Results: The treatment effect of group Ⅱ, FEV_1, PEF, symptom score were close to that of group Ⅰ, there was no significant difference between the two groups (P> 0.05). In terms of safety, the incidence of adverse reactions in group Ⅱ was lower than that in the control group (P <0.05). Conclusion: The combination of theophylline and theophylline and long-acting β_2 receptor agonist has some effects on the treatment of asthma, but the long-acting β_2 receptor agonist is more safe and can be combined with the patient’s condition.